A possible explanation is that baricitinib treatment decreased inflammatory biomarkers associated with DKD pathophysiology, including CCL2 (MCP-1), CXCL10 (IP-10), SSA, tumor necrosis factor receptor (STNFR)1 and STNFR2, VCAM1, and intercellular adhesion molecule-1 (ICAM-1).378 Baricitinib has also been studied in many animal models to investigate its potential for broader clinical application, such as in human immunodeficiency virus (HIV)-associated neurocognitive disorders and osteoporosis.379,380. Here, CXCL10 is linked to diabetic kidney disease.